id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2008-D-0629-0027,FDA,FDA-2008-D-0629,Withdrawal Letter From CDER ORP,Other,Withdrawal,2015-05-29T04:00:00Z,2015,5,2015-05-29T04:00:00Z,,2015-05-29T18:49:37Z,,0,0,0900006481b0e4c0
FDA-2008-D-0629-0001,FDA,FDA-2008-D-0629,Draft Guidance for Industry on Genotoxic and Carcinogenic Impurities in Drug Substances and Products: Recommended Approaches; Availability,Notice,NAD-Notice of Availability of Data,2008-12-16T05:00:00Z,2008,12,2008-02-15T05:00:00Z,2009-02-18T04:59:59Z,2009-02-13T13:25:56Z,E8-29674,0,0,09000064807dd829
FDA-2008-D-0629-0002,FDA,FDA-2008-D-0629,Guidance for Industry Genotoxic and Carcinogenic Impurities in Drug Substances and Products: Recommended Approaches - Guidance,Other,GDL-Guidance (Supporting and Related Materials),2008-12-16T05:00:00Z,2008,12,2008-12-15T05:00:00Z,,2009-02-13T13:28:54Z,,0,0,09000064807ddb80